|
The endocannabinoids1,2 present a rich system of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation. Arachidoyl ethanolamide is one of the saturated fatty acyl ethanolamides devoid of classical (CB1/CB2) activity. Arachidoyl ethanolamide does not bind to the murine CB1 receptor3 and does not compete with anandamide as a substrate for the endocannabinoid hydrolytic enzyme fatty acid amide hydrolase.4 Non-CB receptor-mediated pharmacology of the saturated ethanolamides is still being elucidated.5
|
|
1
Martin, B.R., Mechoulam, R., Razdan, R.K. Discovery and characterization of endogenous cannabinoids. Life Sci 65 573-595 (1999).
2
Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. Current Medicinal Chemistry 6 635-664 (1999).
3
Sheskin, T., Hanus, L., Slager, J., et al. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 40 659-667 (1997).
4
Desarnaud, F., Cadas, H., Piomelli, D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 270(11) 6030-6035 (1995).
5
Smart, D., Jonsson, K., Vandevoorde, S., et al. “Entourage” effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136 452-458 (2002).
|